141 related articles for article (PubMed ID: 17603751)
1. 1 alpha-Hydroxyvitamin D2 inhibits growth of human neuroblastoma.
van Ginkel PR; Yang W; Marcet MM; Chow CC; Kulkarni AD; Darjatmoko S; Lindstrom MJ; Lokken J; Bhattacharya S; Albert DM
J Neurooncol; 2007 Dec; 85(3):255-62. PubMed ID: 17603751
[TBL] [Abstract][Full Text] [Related]
2. Toxicity and dose-response studies of 1-alpha hydroxyvitamin D2 in LH-beta-tag transgenic mice.
Dawson DG; Gleiser J; Zimbric ML; Darjatmoko SR; Lindstrom MJ; Strugnell SA; Albert DM
Ophthalmology; 2003 Apr; 110(4):835-9. PubMed ID: 12689912
[TBL] [Abstract][Full Text] [Related]
3. Toxicity and dose-response studies of 1alpha-hydroxyvitamin D2 in a retinoblastoma xenograft model.
Grostern RJ; Bryar PJ; Zimbric ML; Darjatmoko SR; Lissauer BJ; Lindstrom MJ; Lokken JM; Strugnell SA; Albert DM
Arch Ophthalmol; 2002 May; 120(5):607-12. PubMed ID: 12003610
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of vitamin D analogues in treating large tumors and during prolonged use in murine retinoblastoma models.
Albert DM; Kumar A; Strugnell SA; Darjatmoko SR; Lokken JM; Lindstrom MJ; Patel S
Arch Ophthalmol; 2004 Sep; 122(9):1357-62. PubMed ID: 15364716
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of 1alpha-hydroxyvitamin D2 in inhibiting tumor growth in a murine transgenic pigmented ocular tumor model.
Albert DM; Kumar A; Strugnell SA; Darjatmoko SR; Lokken JM; Lindstrom MJ; Damico CM; Patel S
Arch Ophthalmol; 2004 Sep; 122(9):1365-9. PubMed ID: 15364717
[TBL] [Abstract][Full Text] [Related]
6. Toxicity and dose-response studies of 1 alpha-hydroxyvitamin D2 in LH beta-Tag transgenic mice.
Dawson DG; Gleiser J; Zimbric ML; Darjatmoko SR; Frisbie JC; Lokken JM; Lindstrom MJ; Audo I; Strugnell SA; Albert DM
Trans Am Ophthalmol Soc; 2002; 100():125-9. PubMed ID: 12545685
[TBL] [Abstract][Full Text] [Related]
7. 1,24(S)-dihydroxyvitamin D2, an endogenous vitamin D2 metabolite, inhibits growth of breast cancer cells and tumors.
Zinser GM; Tribble E; Valrance M; Urben CM; Knutson JC; Mazess RB; Strugnell SA; Welsh J
Anticancer Res; 2005; 25(1A):235-41. PubMed ID: 15816543
[TBL] [Abstract][Full Text] [Related]
8. Responsiveness of human retinoblastoma and neuroblastoma models to a non-calcemic 19-nor Vitamin D analog.
Albert DM; Plum LA; Yang W; Marcet M; Lindstrom MJ; Clagett-Dame M; DeLuca HF
J Steroid Biochem Mol Biol; 2005 Oct; 97(1-2):165-72. PubMed ID: 16055326
[TBL] [Abstract][Full Text] [Related]
9. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.
Chen TC; Schwartz GG; Burnstein KL; Lokeshwar BL; Holick MF
Clin Cancer Res; 2000 Mar; 6(3):901-8. PubMed ID: 10741714
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D3-3beta-(2)-Bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D3 in prostate cancer cells.
Swamy N; Chen TC; Peleg S; Dhawan P; Christakos S; Stewart LV; Weigel NL; Mehta RG; Holick MF; Ray R
Clin Cancer Res; 2004 Dec; 10(23):8018-27. PubMed ID: 15585637
[TBL] [Abstract][Full Text] [Related]
11. Metabolism of 1 alpha-hydroxyvitamin D2 to activated dihydroxyvitamin D 2 metabolites decreases endogenous 1 alpha, 25-dihydroxyvitamin D 3 in rats and monkeys.
Knutson JC; Hollis BW; LeVan LW; Valliere C; Gould KG; Bishop CW
Endocrinology; 1995 Nov; 136(11):4749-53. PubMed ID: 7588202
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo.
Tanno B; Mancini C; Vitali R; Mancuso M; McDowell HP; Dominici C; Raschellà G
Clin Cancer Res; 2006 Nov; 12(22):6772-80. PubMed ID: 17121898
[TBL] [Abstract][Full Text] [Related]
13. Antineoplastic effect and toxicity of 1,25-dihydroxy-16-ene-23-yne-vitamin D3 in athymic mice with Y-79 human retinoblastoma tumors.
Sabet SJ; Darjatmoko SR; Lindstrom MJ; Albert DM
Arch Ophthalmol; 1999 Mar; 117(3):365-70. PubMed ID: 10088815
[TBL] [Abstract][Full Text] [Related]
14. Vitamin D analogs, a new treatment for retinoblastoma: The first Ellsworth Lecture.
Albert DM; Nickells RW; Gamm DM; Zimbric ML; Schlamp CL; Lindstrom MJ; Audo I
Ophthalmic Genet; 2002 Sep; 23(3):137-56. PubMed ID: 12324873
[TBL] [Abstract][Full Text] [Related]
15. 1alpha-hydroxyvitamin D2 is less toxic but not bone selective relative to 1alpha-hydroxyvitamin D3 in ovariectomized rats.
Weber K; Goldberg M; Stangassinger M; Erben RG
J Bone Miner Res; 2001 Apr; 16(4):639-51. PubMed ID: 11315991
[TBL] [Abstract][Full Text] [Related]
16. β-Carotene inhibits neuroblastoma cell invasion and metastasis in vitro and in vivo by decreasing level of hypoxia-inducible factor-1α.
Kim YS; Lee HA; Lim JY; Kim Y; Jung CH; Yoo SH; Kim Y
J Nutr Biochem; 2014 Jun; 25(6):655-64. PubMed ID: 24746828
[TBL] [Abstract][Full Text] [Related]
17. Radioligand receptor assay for 25-hydroxyvitamin D2/D3 and 1 alpha, 25-dihydroxyvitamin D2/D3.
Hughes MR; Baylink DJ; Jones PG; Haussler MR
J Clin Invest; 1976 Jul; 58(1):61-70. PubMed ID: 1084355
[TBL] [Abstract][Full Text] [Related]
18. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
19. Temporal changes in tissue 1α,25-dihydroxyvitamin D3, vitamin D receptor target genes, and calcium and PTH levels after 1,25(OH)2D3 treatment in mice.
Chow EC; Quach HP; Vieth R; Pang KS
Am J Physiol Endocrinol Metab; 2013 May; 304(9):E977-89. PubMed ID: 23482451
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of a non-hypercalcemic vitamin-D2 derived anti-cancer agent (MT19c) and inhibition of fatty acid synthesis in an ovarian cancer xenograft model.
Moore RG; Lange TS; Robinson K; Kim KK; Uzun A; Horan TC; Kawar N; Yano N; Chu SR; Mao Q; Brard L; DePaepe ME; Padbury JF; Arnold LA; Brodsky A; Shen TL; Singh RK
PLoS One; 2012; 7(4):e34443. PubMed ID: 22509304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
